Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 12/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | USP14 | P54578 | 4/20 | 0.31 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.31 |
| ▸ | VHL | P40337 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26612863 | 1.00 | KRAS (0.34) | KRASPIK3CDUSP14EIF4EBP1VHL | |
| SCHEMBL26672499 | 0.91 | KRAS (0.35) | KRASPIK3CDUSP14EIF4EBP1VHL | |
| SCHEMBL26672478 | 0.91 | KRAS (0.35) | KRASPIK3CDUSP14EIF4EBP1VHL | |
| SCHEMBL26852191 | 0.87 | KRAS (0.36) | KRASFNTAFNTB | |
| SCHEMBL29914750 | 0.87 | KRAS (0.36) | KRASFNTAFNTB | |
| SCHEMBL26738599 | 0.87 | KRAS (0.36) | KRASFNTAFNTB | |
| SCHEMBL26612723 | 0.86 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL26612717 | 0.86 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL29914720 | 0.85 | IDH1 (0.35) | KRASPIK3CDEIF4EBP1SOS1 | |
| SCHEMBL22554819 | 0.81 | KRAS (0.38) | KRASPIK3CDSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140948-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4281457-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Beta Pharma, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-113999226-B | Heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-113999226-A | Heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140948-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885PIK3CD 149/4885USP14 3410/4885 |
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | KRAS, NRAS, HRAS | KRAS 1/4885PIK3CD 345/4885USP14 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.